Barclays raised the firm’s price target on Humana (HUM) to $253 from $250 and keeps an Equal Weight rating on the shares post the Q3 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana’s Medicare Advantage Star Ratings Drop: Legal Battle Looms Over 2025 Projections and Potential Revenue Impact
- Humana Inc. Reports Mixed Q3 2024 Results
- HUM Earnings: Humana Reports Better-than-Expected Q3 Results, Updates Outlook
- Humana: 3% margin target for 2027 ‘realistic,’ but ‘at risk’
- Humana to approach 2025 with ‘similar posture’ as Q3 strategy